Meeting
2011 ASCO Annual Meeting
Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data.
Authors
H. R. Carlson
University of Texas M. D. Anderson Cancer Center, Houston, TX
H. R. Carlson , S. Karanth , M. A. Zarzour , R. Lenzi , M. N. Raber , G. R. Varadhachary
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4123)
Abstract #
4123
Poster Bd #
38A
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2024 ASCO Annual Meeting
Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies.
First Author: Marco Maria Germani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database.
First Author: Yu Sunakawa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.
First Author: Kodai Takemori